Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CNMD
stocks logo

CNMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
366.82M
+6.04%
1.324
-1.23%
339.17M
+5.58%
1.018
+7.11%
361.35M
+5.55%
1.192
+3.7%
Estimates Revision
The market is revising Upward the revenue expectations for CONMED Corporation (CNMD) for FY2025, with the revenue forecasts being adjusted by 0.05% over the past three months. During the same period, the stock price has changed by -19.52%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.05%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.63%
In Past 3 Month
Stock Price
Go Down
down Image
-19.52%
In Past 3 Month
Wall Street analysts forecast CNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNMD is 53.50 USD with a low forecast of 52.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast CNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNMD is 53.50 USD with a low forecast of 52.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 44.240
sliders
Low
52.00
Averages
53.50
High
55.00
Current: 44.240
sliders
Low
52.00
Averages
53.50
High
55.00
Piper Sandler
Matt O'Brien
Overweight
downgrade
$68 -> $55
2025-11-06
Reason
Piper Sandler
Matt O'Brien
Price Target
$68 -> $55
2025-11-06
downgrade
Overweight
Reason
Piper Sandler analyst Matt O'Brien lowered the firm's price target on Conmed to $55 from $68 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that were roughly in-line with its estimates on the top-and-bottom line. Management essentially kept its revenue guidance for the year unchanged but did lower EPS by three cents, Piper adds.
JPMorgan
Neutral
downgrade
$58 -> $52
2025-11-06
Reason
JPMorgan
Price Target
$58 -> $52
2025-11-06
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Conmed to $52 from $58 and keeps a Neutral rating on the shares. The company reported a good Q3 amid "slow and steady" supply and execution improvements, the analyst tells investors in a research note.
Needham
Buy
to
Hold
downgrade
2025-06-12
Reason
Needham
Price Target
2025-06-12
downgrade
Buy
to
Hold
Reason
Needham downgraded Conmed to Hold from Buy without a price target. The company's long-term growth rate has decreased, mainly due to slower AirSeal and Buffalo Filter growth, the analyst tells investors in a research note. The firm believes the slower revenue growth is likely to drive more gradual margin improvement and slower earnings growth at Conmed. In addition, the company's debt level limits its ability to acquire new growth drivers or to repurchase shares, contends Needham. The firm says Conmed's outlook has deteriorated while the shares no longer at a discount given that peer multiples have contracted.
JP Morgan
Robbie Marcus
Buy
to
Hold
Downgrades
$85 → $70
2025-02-06
Reason
JP Morgan
Robbie Marcus
Price Target
$85 → $70
2025-02-06
Downgrades
Buy
to
Hold
Reason
Needham
Mike Matson
Strong Buy
Maintains
$97 → $91
2025-02-06
Reason
Needham
Mike Matson
Price Target
$97 → $91
2025-02-06
Maintains
Strong Buy
Reason
Wells Fargo
Vik Chopra
Hold
Maintains
$74 → $70
2025-02-06
Reason
Wells Fargo
Vik Chopra
Price Target
$74 → $70
2025-02-06
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Conmed Corp (CNMD.N) is 9.50, compared to its 5-year average forward P/E of 26.67. For a more detailed relative valuation and DCF analysis to assess Conmed Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
26.67
Current PE
9.50
Overvalued PE
37.73
Undervalued PE
15.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
15.68
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
20.42
Undervalued EV/EBITDA
10.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.45
Current PS
0.00
Overvalued PS
3.38
Undervalued PS
1.52
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CNMD News & Events

Events Timeline

(ET)
2025-11-05
16:56:03
Conmed revises FY25 adjusted EPS forecast to a range of $4.48-$4.53, down from $4.40-$4.55.
select
2025-11-05
16:54:35
Conmed announces Q3 adjusted EPS of $1.08, surpassing consensus estimate of $1.05
select
2025-07-30 (ET)
2025-07-30
16:10:25
Conmed cuts FY25 EPS view to $4.40-$4.55 from $4.45-$4.60, consensus $4.40
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
12-04NASDAQ.COM
Reasons to Consider Adding CONMED Stock to Your Portfolio Today

  • Growth Potential: CONMED Corporation is positioned for growth due to the rising adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, alongside increasing robotic procedure volumes and the expansion of Ambulatory Surgery Centers (ASCs).

  • Challenges and Delays: The company faces tariff-related gross margin pressures and delays in AirSeal adoption due to the integration of Intuitive Surgical’s dV5 system, which includes its own insufflation system, impacting immediate sales opportunities.

  • Supply Chain Improvements: Progress in supply chain recovery is expected to enhance product availability and support growth in the orthopedics business, although the full recovery may take several quarters.

  • Strategic Focus: A portfolio review is guiding CONMED to concentrate on high-return segments such as minimally invasive surgery and orthopedic soft-tissue repair, aiming to improve margins and long-term competitiveness.

[object Object]
Preview
8.0
11-14NASDAQ.COM
Maximizing CNMD Yield to 21.1% Through Options Strategies

  • Dividend Predictability: Dividend amounts for companies like CONMED Corp are influenced by profitability and may not be predictable, with a current annualized yield of 1.9% under consideration.

  • Stock Trading History: A chart of CNMD's trading history highlights the $45 strike price, which can be used to assess the potential risks and rewards of selling covered calls.

  • Volatility Analysis: CONMED Corp's trailing twelve-month volatility is calculated at 42%, which can aid in evaluating options strategies.

  • Options Myths: The article references common myths about options, including the notion that most options expire worthless, and encourages further exploration of call options available for CNMD.

[object Object]
Preview
3.0
11-06NASDAQ.COM
Conmed to Hold Q3 2025 Earnings Conference Call at 4:30 PM ET
  • Conference Call Announcement: Conmed Corp. will hold a conference call on November 5, 2025, at 4:30 PM ET to discuss its Q3 25 earnings results.
  • Webcast Access: Interested parties can access the live webcast of the conference call through the provided link.
  • Author's Views Disclaimer: The opinions expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
  • Earnings Discussion Focus: The conference call will specifically focus on the financial performance of Conmed Corp. for the third quarter of fiscal year 2025.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Conmed Corp (CNMD) stock price today?

The current price of CNMD is 44.24 USD — it has decreased -0.25 % in the last trading day.

arrow icon

What is Conmed Corp (CNMD)'s business?

CONMED Corporation is a medical technology company, which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.

arrow icon

What is the price predicton of CNMD Stock?

Wall Street analysts forecast CNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNMD is 53.50 USD with a low forecast of 52.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Conmed Corp (CNMD)'s revenue for the last quarter?

Conmed Corp revenue for the last quarter amounts to 337.93M USD, increased 6.70 % YoY.

arrow icon

What is Conmed Corp (CNMD)'s earnings per share (EPS) for the last quarter?

Conmed Corp. EPS for the last quarter amounts to 0.09 USD, decreased -94.27 % YoY.

arrow icon

What changes have occurred in the market's expectations for Conmed Corp (CNMD)'s fundamentals?

The market is revising Upward the revenue expectations for CONMED Corporation (CNMD) for FY2025, with the revenue forecasts being adjusted by 0.05% over the past three months. During the same period, the stock price has changed by -19.52%.
arrow icon

How many employees does Conmed Corp (CNMD). have?

Conmed Corp (CNMD) has 3900 emplpoyees as of December 05 2025.

arrow icon

What is Conmed Corp (CNMD) market cap?

Today CNMD has the market capitalization of 1.37B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free